Project Grant R21DA061319
Award Date 8/15/25
Completion Date 7/31/27
Dollars Obligated $190K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This Project Grant award for $423,708 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding will support research to investigate the effects of fentanyl-xylazine drug mixtures on cardiorespiratory function and subjective effects in rats. Specifically, the research aims to characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure, temperature, and respiration, as well as determine if...
- The Project Grant award of $231,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research at the University of Rochester to determine if the drug xylazine and its metabolites act as agonists or positive allosteric modulators at the mu and kappa opioid receptors. Additional studies will investigate whether xylazine and its metabolites are agonists, antagonists, or inverse agonists at the sigma 1 and sigma 2 receptors....
- This $197,024 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports two multi-methods studies to characterize the impact of the veterinary tranquilizer xylazine on people who use drugs (PWUD) in North Carolina and Maine. The first study in North Carolina aims to describe PWUD's perceptions and experiences with xylazine and related complications, such as overdoses and skin ulcers, through surveys...
- The U.S. National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $293,587 Project Grant to The Regents of the University of California, San Francisco (UCSF) to investigate the potential causticity or acidity of the drug combination known as "Tranq," which is a combination of the non-FDA-approved animal tranquilizer xylazine and the synthetic opioid fentanyl. The project aims to use qualitative and quantitative methods,...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a 5-year Project Grant of $184,706 to the University of North Carolina at Chapel Hill (UNC-CH) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will fund research to investigate the impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala, a key component of the stress response. Specifically, the project will develop a mouse model of...
- This Project Grant award, valued at $506,000.00 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the Scripps Research Institute to develop monoclonal antibodies that can block the mechanism of action and adverse effects of the drug xylazine. Xylazine has emerged as an adulterant in illicit drug mixtures, contributing to overdose deaths, and this research aims to create novel therapeutic...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $238,500 to the University of Pittsburgh to conduct research on the effects of xylazine and opioids on prefrontal cortex inhibitory transmission. The research aims to understand xylazine's cell signaling profiles and interactions with opioids at the circuit level, as xylazine is becoming highly prevalent in illicit opioid supplies and poses an...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $495,950 to The Washington University in Missouri to investigate the mechanisms involving mu opioid receptor (MOR) signaling within the nucleus of the solitary tract (NTS) that contribute to fentanyl-induced cardiorespiratory depression. The 3-year project, commencing on Sept 1, 2025, aims to employ various techniques such as chemogenetics, optogenetics, and...
- This $387,750 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research by Mercer University to investigate the molecular pharmacology of the drug xylazine and its effects on adrenoceptors. The research aims to assess xylazine's binding affinity and functional profiles at different adrenoceptor subtypes expressed in vascular smooth muscle cells, as well as directly test the hypothesis that...
- This Project Grant award in the amount of $428,432 was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The objective of this project is to advance the basic understanding of the mechanism of action and structure-activity relationship of the highly potent synthetic opioid derivatives known as "nitazenes" in comparison to fentanyl. The project will leverage state-of-the-art simulations, machine learning, and experimental...